© 2005 Oxford University Press
ARTICLE |
Cervical Cancer in Women With Comprehensive Health Care Access: Attributable Factors in the Screening Process
Affiliations of authors: Kaiser Permanente Division of Research, Oakland, CA (WAL, MMM); Kaiser Permanente Southern California Research and Evaluation, Pasadena, CA (AMG); Kaiser Permanente Center for Health Research, Northwest, Portland, OR (SW); Kaiser Permanente Clinical Research Unit, Denver, CO (JM, KB); Josephine Ford Cancer Center, Henry Ford Health System, Detroit, MI (MUY); Kaiser Permanente, Hawaii, Honolulu, HI (JG); Group Health Cooperative, Seattle, WA (SHT)
Correspondence to: M. Michele Manos, PhD, MPH, Kaiser Permanente Division of Research, 2000 Broadway, Oakland, CA 94612 (e-mail: michele.manos{at}kp.org).
Background: Invasive cervical cancer is highly preventable, yet it continues to occur, even among women who have access to cancer screening and treatment services. To reduce cervical cancer among such women, reasons for its occurrence must be better understood. We examined factors associated with the diagnosis of cervical cancer among women enrolled in health plans. Methods: We identified all cases of invasive cervical cancer (n = 833) diagnosed from January 1, 1995, through December 31, 2000, among women who were long-term members of seven prepaid comprehensive health plans and reviewed each woman's medical records for the 3 years prior to her cancer diagnosis. Women were classified into one of three categories based on Pap test histories 4–36 months before diagnosis: failure to screen with a Pap test, failure in detection by a Pap test, or failure in follow-up of an abnormal test result. Results: The majority of cases (n = 464; 56%) were in women who had no Pap tests during the period 4–36 months prior to diagnosis. Of the remaining cases, 263 (32%) were attributed to Pap test detection failure and 106 (13%) to follow-up failure. Being older (odds ratio [OR] = 6.48, 95% confidence interval [CI] = 3.89 to 10.79) or living in an area of higher poverty (OR = 1.72, 95% CI = 1.11 to 2.67) or having a lower education level (OR= 1.52; 95% CI = 1.07 to 2.16) was associated with the likelihood of being assigned to the failure to screen category versus either of the other two categories. A total of 375 (81%) of the 464 patients who had not had Pap screening had had at least one outpatient visit 4–36 months prior to cancer diagnosis. The cancer diagnostic process was triggered by a routine screening examination in 44% of patients, whereas 53% of the patients presented with symptoms consistent with cervical cancer; the remaining 3% were identified fortuitously during the course of receiving noncervical care. Conclusions: To reduce the incidence of invasive cervical cancer among women with access to screening and treatment, Pap screening adherence should be increased. In addition, strategies to improve the accuracy of Pap screening could afford earlier detection of cervical cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. R. Yabroff, M. Saraiya, H. I. Meissner, D. A. Haggstrom, L. Wideroff, G. Yuan, Z. Berkowitz, W. W. Davis, V. B. Benard, and S. S. Coughlin Specialty Differences in Primary Care Physician Reports of Papanicolaou Test Screening Practices: A National Survey, 2006 to 2007 Ann Intern Med, November 3, 2009; 151(9): 602 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Wheeler, W. C. Hunt, N. E. Joste, C. R. Key, W. G. V. Quint, and P. E. Castle Human Papillomavirus Genotype Distributions: Implications for Vaccination and Cancer Screening in the United States J Natl Cancer Inst, April 1, 2009; 101(7): 475 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Giorgi Rossi and M. Zappa Re: Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 Vaccination J Natl Cancer Inst, November 19, 2008; 100(22): 1654 - 1654. [Full Text] [PDF]
|
|
|
|
|
|
J. D. Goldhaber-Fiebert and S. Goldie Response J Natl Cancer Inst, November 19, 2008; 100(22): 1654 - 1655. [Full Text] [PDF]
|
|
|
|
|
|
B. Andrae, L. Kemetli, P. Sparen, L. Silfverdal, B. Strander, W. Ryd, J. Dillner, and S. Tornberg Screening-Preventable Cervical Cancer Risks: Evidence From a Nationwide Audit in Sweden J Natl Cancer Inst, May 7, 2008; 100(9): 622 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-C. Chang, H.-Y. Hsiung, S.-I Chen, A. M.-F. Yen, and T. H.-H. Chen Comparison of a community outreach service with opportunity screening for cervical cancer using Pap smears J. Public Health Med., June 1, 2007; 29(2): 165 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Bock and B. M. Kwan Encouragement of Patient Self-management and Adherence through Use of a Computerized Tracking System for Cervical and Colon Cancer Screening J Am Board Fam Med, May 1, 2007; 20(3): 316 - 319. [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Wallace Reshaping Cancer Learning Through The Use Of Health Information Technology Health Aff., March 1, 2007; 26(2): w169 - w177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Katz, M. E. Wewers, N. Single, and E. D. Paskett Key Informants' Perspectives Prior to Beginning a Cervical Cancer Study in Ohio Appalachia Qual Health Res, January 1, 2007; 17(1): 131 - 141. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Saslow, P. E. Castle, J. T. Cox, D. D. Davey, M. H. Einstein, D. G. Ferris, S. J. Goldie, D. M. Harper, W. Kinney, A.-B. Moscicki, et al. American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors CA Cancer J Clin, January 1, 2007; 57(1): 7 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Zapka, E. Puleo, S. Taplin, L. I. Solberg, J. Mouchawar, C. Somkin, A. M. Geiger, and M. U. Yood Breast and Cervical Cancer Screening: Clinicians' Views on Health Plan Guidelines and Implementation Efforts J Natl Cancer Inst Monographs, November 1, 2005; 2005(35): 46 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Tanne Cervical cancer is still missed, despite the availability of screening BMJ, May 14, 2005; 330(7500): 1102 - 1102. [Full Text] [PDF]
|
|